Globally, the figure could reach 139 million by 2050 without an effective treatment, Alzheimer's Disease International said.
Aduhelm was the first new Alzheimer's drug approved in 20 years after a long list of high-profile failures for the industry.
read morePatient advocacy groups hailed the news of positive lecanemab trial results.
Micro hemorrhages in the brain occurred at a rate of 17% in the lecanemab group, and 8.7% in the placebo group.
Aduhelm's approval was a rare bright spot for Alzheimer's patients, but critics have called for more evidence that amyloid-targeting drugs are worth the cost.